Table 3.

Baseline characteristics of patients who discontinued DMF with grade II–III lymphopenia

Patients	Grade II–III lymphopenia (n = 51)	Grade II lymphopenia (n = 23)	Grade III lymphopenia (n = 28)
Female sex [n (%)]	44 (86.3)	21 (91.3)	23 (82.1)
Age, years	45.9 (10.7)	44.4 (11.6)	47.1 (10.1)
Time since first symptom, years	10.9 (8.8)	9.7 (8.4)	11.9 (9.0)
EDSS score, median [range]	2.0 [0.0–6.0]	2.0 [0.0–6.0]	2.0 [0.0–6.0]
Treatment naïves [n (%)]	19 (37.2)	9 (39.1)	10 (35.7)
Prior DMDs [n (%)]  Glatiramer acetate [n (%)]  Interferon beta 1 a [n (%)]  Interferon beta 1 b [n (%)]  Teriflunomide [n (%)]  Azathioprine [n (%)]  Fingolimod [n (%)]  Natalizumab [n (%)]	9 (28.1) 13 (40.6) 3 (9.4) 2 (6.3) 1 (3.2) 3 (9.4) 1 (3.2)	5 (21.7) 4 (17.4) 1 (4.3) 2 (8.7) 1 (4.3) 1 (4.3) 0 (0.0)	4 (14.3) 9 (32.1) 2 (7.1) 0 (0.0) 0 (0.0) 2 (7.1) 1 (3.6)
Follow-up in months on DMF	22.3 (± 11.9)	23.0 (± 12.1)	21.7 (± 11.8)
Lymphopenia duration before DMF withdrawal (months)	11.2 (± 9.7)	11.2 (± 8.7)	11.2 (± 10.6)
Time to lymphocyte count recovery (months), median [range]	3.4 [0.3–13.7]	2.5 [0.3–8.4]	5.2 [0.5–13.7]

DMF dimethyl fumarate, EDSS Expanded Disability Status Score, DMD disease modifying drug

All values are reported as mean (standard deviation) unless indicated otherwise